Objectives: This study was conducted to evaluate the effectiveness of the combination therapy of Saengmaek-san decoction and Western medicine on heart failure. Methods: A search was conducted on June 22, 2024 using keywords such as "heart failure", "saengmaeksan", and "shengmaisan". A meta-analysis was conducted according to the outcome measurements such as the total effective rate (TER), serum B-type natriuretic peptide (BNP), echocardiography results (left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), stroke volume (SV)), and six-minute walk test (6MWT). Data analysis was performed using the RevMan 5.4.1 software, and Cochrane's risk of bias (ROB) was used to assess the quality of the papers. Results: A total of eight randomized control trials were selected. The treatment group combining Saengmaek-san and Western medicine showed significant improvement effects in terms of TER, BNP, LVEF, LVESD, LVEDD, SV, and 6MWT compared to the control group using Western medicine alone [TER] RR=1.23, 95% CI: 1.13-1.34, p<0.00001; [BNP] MD=-206.14, 95% CI : -257.49--154.79, p<0.00001; [LVEF] MD=6.40, 95% CI : 5.54-7.27, p<0.00001; [LVEDD] MD=-6.55, 95% CI : -7.24--5.85, p<0.00001; [LVESD] MD=-3.07, 95% CI: -3.92--2.22, p<0.00001; [SV] MD=7.12, 95% CI : 5.73-8.50, p<0.00001; [6MWT] MD=43.69, 95% CI : 31.55-55.84, p<0.00001. Conclusion: This study suggests that the combination therapy of Saengmaek-san decoction and Western medicine is effective in treating heart failure. However, these findings should be interpreted cautiously due to the unknown or high risk of bias in the included trials.